Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many drugs are designed to target tumor-specific antigens, which are molecules ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

Pediatric patients with ALL were found to experience deficits in their motor skills between at least 1 month and 4 years after completing treatment.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left without hope.” ...

was well tolerated and demonstrated an overall response rate of 74% in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in a real-world study. "The INO‐CD22 ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...